サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1166122

抗凝固拮抗薬の世界市場：成長、将来の見通し、競合分析（2022年～2030年）

Anticoagulant Reversal Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
抗凝固拮抗薬の世界市場：成長、将来の見通し、競合分析（2022年～2030年）
出版日: 2022年08月24日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗凝固拮抗薬の市場規模は、2022年～2030年の間の予測期間中に15.3%のCAGRで成長すると予測されています。

当レポートでは、世界の抗凝固拮抗薬市場について調査分析し、市場動向、市場力学、セグメント別・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主要な製品
  • 市場の内訳
  • 調査手法
    • フェーズI：2次調査
    • フェーズII：1次調査
    • フェーズIII：専門家別審査
    • 前提条件
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場のスナップショット：世界の抗凝固拮抗薬市場
  • 世界の抗凝固拮抗薬市場（2021年）
  • 世界の抗凝固拮抗薬市場：薬剤クラス別（2021年）
  • 世界の抗凝固拮抗薬市場：地域別（2021年）
  • COVID-19の影響
  • 魅力的な投資提案：地域別（2021年）
  • 競合分析
    • 主要な抗凝固拮抗薬市場ベンダーの市場ポジショニング
    • 抗凝固拮抗薬市場ベンダーが採用する戦略
    • 主要な業界戦略

第3章 抗凝固拮抗薬市場：ビジネスの見通しと市場力学

  • イントロダクション
  • 抗凝固拮抗薬の市場価値（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主要な課題
    • 主要な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治情勢
    • 経済情勢
    • 技術情勢
    • 法的情勢
    • 社会情勢

第4章 抗凝固拮抗薬市場（2020年～2030年）

  • 市場概要
  • 成長・収益分析：2021年対2030年
  • 市場の内訳

第5章 抗凝固拮抗薬市場：薬剤クラス別（2020年～2030年）

  • 市場概要
  • 成長・収益分析：2021年対2030年
  • 市場の内訳
    • プロトロンビン複合体濃縮物（PCC）
    • ビタミンK
    • プロタミン
    • トラネキサム酸
    • デスモプレシン
    • イダルシズマブ
    • アンデクサ
    • パイプライン分析
    • フェーズⅢ薬（2026年までの予測）
    • オクタプレックス
    • フェーズI・IIの薬剤

第6章 北米の抗凝固拮抗薬市場（2020年～2030年）

  • 市場概要
  • 2020年～2030年
  • 薬剤クラス別（2020年～2030年）
  • 地域別（2020年～2030年）
    • 北米

第7章 英国・EUの抗凝固拮抗薬市場（2020年～2030年）

  • 市場概要
  • 2020年～2030年
  • 薬剤クラス別（2020年～2030年）
  • 地域別（2020年～2030年）
    • 英国・EU

第8章 アジア太平洋の抗凝固拮抗薬市場（2020年～2030年）

  • 市場概要
  • 2020年～2030年
  • 薬剤クラス別（2020年～2030年）
  • 地域別（2020年～2030年）
    • アジア太平洋

第9章 ラテンアメリカの抗凝固拮抗薬市場（2020年～2030年）

  • 市場概要
  • 2020年～2030年
  • 薬剤クラス別（2020年～2030年）
  • 地域別（2020年～2030年）
    • ラテンアメリカ

第10章 中東・アフリカの抗凝固拮抗薬市場（2020年～2030年）

  • 市場概要
  • 2020年～2030年
  • 薬剤クラス別（2020年～2030年）
  • 地域別（2020年～2030年）
    • 中東・アフリカ

第11章 企業プロファイル

  • Boehringer Ingelheim GmbH
  • Fresenius Kabi AG
  • Pfizer, Inc.
  • Bausch Health Companies, Inc.
  • Amneal Pharmaceuticals, Inc.
  • CSL Behring Limited
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • Perosphere Pharmaceuticals, Inc.
  • Ferring Pharmaceuticals
図表

List of Tables

  • TABLE 1 Global Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 2 Global Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 3 North America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 4 North America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 5 UK and European Union Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 7 Asia Pacific Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 8 Asia Pacific Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 9 Latin America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 10 Latin America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 11 Middle East and Africa Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 12 Middle East and Africa Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Anticoagulant Reversal Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Anticoagulant Reversal Drugs Market: Quality Assurance
  • FIG. 5 Global Anticoagulant Reversal Drugs Market, By , 2021
  • FIG. 6 Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021
  • FIG. 7 Global Anticoagulant Reversal Drugs Market, By Geography, 2021
  • FIG. 8 Global Anticoagulant Reversal Drugs Market, By , 2021 Vs 2030, %
  • FIG. 9 Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021 Vs 2030, %
  • FIG. 10 U.S. Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 11 Canada Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Rest of North America Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 UK Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 Germany Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Spain Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Italy Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 France Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 Rest of Europe Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 China Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 Japan Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 India Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 Australia Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 South Korea Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 Rest of Asia Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Brazil Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Mexico Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Latin America Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 GCC Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 Africa Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
目次
Product Code: 138615-08-22

Industry Outlook

The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2022 to 2030. Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT). However, this growth in anticoagulants usage has led to the rise in the incidence of hospitals admissions and death due to increased bleeding due to anticoagulation. According to Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in U.S. alone and close to 2,000 deaths per month attributable to anticoagulation or factor Xa inhibitor related bleeding. These factors have led to furious research and development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) has granted special status and accelerated approvals for development and swift market entry of certain anticoagulant antidotes.

"Recent Approval of First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market"

In May 2018, The U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing of anticoagulation effects. Andexxa received both orphan drug status and breakthrough designation by U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it to grow at fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drugs market owing to increased use of these agents during critical situation. Idarucizumab, approved in 2015 was the only drug for reversing the anticoagulation effects of dabigatran etexilate mesylate.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anticoagulant Reversal Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anticoagulant Reversal Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Prothrombin Complex Concentrates (PCC)

Vitamin K

Protamine

Tranexmic Acid

Desmopressin

Idarucizumab

Andexxa

Pipeline Analysis

Phase III Drugs (Forecast till 2026)

Octaplex

Phase I and II Drugs (Tabular Representation)

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anticoagulant Reversal Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anticoagulant Reversal Drugs market?

Which is the largest regional market for Anticoagulant Reversal Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anticoagulant Reversal Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anticoagulant Reversal Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Anticoagulant Reversal Drugs Market
  • 2.2. Global Anticoagulant Reversal Drugs Market, By , 2021 (US$ Million)
  • 2.3. Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021 (US$ Million)
  • 2.4. Global Anticoagulant Reversal Drugs Market, By Geography, 2021 (US$ Million)
  • 2.5. Impact of Covid 19
  • 2.6. Attractive Investment Proposition by Geography, 2021
  • 2.7. Competitive Analysis
    • 2.7.1. Market Positioning of Key Anticoagulant Reversal Drugs Market Vendors
    • 2.7.2. Strategies Adopted by Anticoagulant Reversal Drugs Market Vendors
    • 2.7.3. Key Industry Strategies

3. Anticoagulant Reversal Drugs Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Anticoagulant Reversal Drugs Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation

5. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Prothrombin Complex Concentrates (PCC)
    • 5.3.2. Vitamin K
    • 5.3.3. Protamine
    • 5.3.4. Tranexmic Acid
    • 5.3.5. Desmopressin
    • 5.3.6. Idarucizumab
    • 5.3.7. Andexxa
    • 5.3.8. Pipeline Analysis
    • 5.3.9. Phase III Drugs (Forecast till 2026)
    • 5.3.10. Octaplex
    • 5.3.11. Phase I and II Drugs (Tabular Representation)

6. North America Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 6.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 6.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.4.1.North America
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
      • 6.4.1.3. Rest of North America

7. UK and European Union Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 7.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 7.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.UK and European Union
      • 7.4.1.1. UK
      • 7.4.1.2. Germany
      • 7.4.1.3. Spain
      • 7.4.1.4. Italy
      • 7.4.1.5. France
      • 7.4.1.6. Rest of Europe

8. Asia Pacific Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 8.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 8.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.Asia Pacific
      • 8.4.1.1. China
      • 8.4.1.2. Japan
      • 8.4.1.3. India
      • 8.4.1.4. Australia
      • 8.4.1.5. South Korea
      • 8.4.1.6. Rest of Asia Pacific

9. Latin America Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 9.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 9.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Latin America
      • 9.4.1.1. Brazil
      • 9.4.1.2. Mexico
      • 9.4.1.3. Rest of Latin America

10. Middle East and Africa Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 10.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 10.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Middle East and Africa
      • 10.4.1.1. GCC
      • 10.4.1.2. Africa
      • 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

  • 11.1. Boehringer Ingelheim GmbH
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Fresenius Kabi AG
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Pfizer, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Bausch Health Companies, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Amneal Pharmaceuticals, Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. CSL Behring Limited
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Octapharma AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Portola Pharmaceuticals, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Perosphere Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Ferring Pharmaceuticals
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives